Compass Therapeutics (CMPX) Earnings Analysis

Compass Therapeutics (CMPX) next reports earnings on 2026-08-10, consensus EPS -0.1 USD. Last quarter (2026-03-05) it beat with EPS -0.09 USD vs -0.1 USD est (+10%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -4.80.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CMPX next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.1 USD
Revenue estimate-0.00B

CMPX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-05-0.09 USD-0.1 USD+10%Beat
2025-08-11-0.14 USD-0.13 USD-7.7%Miss
2025-02-27-0.11 USD-0.1 USD-10%Miss
2024-08-12-0.1 USD-0.1 USD0%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

CMPX valuation and analyst view

Trailing P/E-4.80
Trailing EPS-0.36573 USD
Price / book2.04
Dividend yield0.00%
Market cap0.28B
Analyst consensusBuy (15 buy / 0 hold / 0 sell)
Avg price target6 USD

Related research pages

Frequently asked questions

When is Compass Therapeutics (CMPX)'s next earnings date?

Compass Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.1 USD and revenue estimate of -0.00B.

Did CMPX beat earnings last quarter?

In its 2026-03-05 report, CMPX posted EPS of -0.09 USD versus a -0.1 USD estimate — a beat of 10%.

What is CMPX's earnings track record?

Over the last 4 reported quarters with consensus data, CMPX beat estimates 2 times (50%).

What is CMPX's current P/E ratio and EPS?

CMPX trades at a trailing P/E of -4.80 on trailing EPS of -0.3657349785407725 USD.

What do analysts rate CMPX?

Analyst consensus is "Buy" across 15 ratings (0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 6 USD.